Market Data 
Markets
Replies to post #484259 on NorthWest Biotherapeutics Inc (NWBO)
From his presentation, Dr. Murthy seems to be behind on “finishing” and “validating” for commercial automation. Did you get a different read from your discussion with Dr. Murthy? Did you get any sense of timeline?
During April 2022, the Company entered into a Statement of Work #6 (“SOW 6”) with Advent that will be incorporated into the Ancillary Services Agreement that was originally entered into dated November 8, 2019 and was extended on July 8, 2021. SOW 6 is for baseline costs and conditional milestone costs related to product and clinical trial matters during the period April 1, 2022 through the end of September 2022. The parties anticipate entering into a separate agreement, as an extension of SOW 5, for work by Advent related to the Sawston facility during Q2 and Q3 of this year, but this work is still in the process of being determined. The total costs under the SOW 6 include estimated baseline costs in the range of $3.2 million to $3.9 million and milestone costs ranging between $1.5 and $8.0 million in cash and 1.5 to 12.5 million in shares, depending upon what milestones are achieved.
AI
